Cargando…

Impact of liver metastases status on survival outcomes of first-line immunotherapy in extensive stage small cell lung cancer: a systematic review and meta-analysis

Purpose: This study aims to assess the impact of liver metastases status on survival outcomes of first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC) patients. Materials and methods: Comprehensive searches were conducted in the Cochrane Library databases, Embase, PubMed, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Yan, Jiang, Wei, Su, Cui-Yun, Pan, Xin-Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2023
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564432/ https://www.ncbi.nlm.nih.gov/pubmed/37724893 http://dx.doi.org/10.18632/aging.205035

Ejemplares similares

Efficacy of First-Line Immunotherapy Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients With Different Brain Metastases Status: A Systematic Review and Meta-Analysis
por: Zhao, Wen Hua, et al.
Publicado: (2023)

Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer
por: Zhang, Shuang, et al.
Publicado: (2021)

IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer
por: Huang, Chengliang, et al.
Publicado: (2020)

Impact of Liver Metastasis on First-Line Immunotherapy in Stage IV Non-Small Cell Lung Cancer
por: Komiya, Takefumi, et al.
Publicado: (2023)

Immunotherapy for extensive stage small cell lung cancer
por: Pacheco, Jose M.
Publicado: (2020)

Immunotherapy in Extensive-Stage Small Cell Lung Cancer
por: El Sayed, Rola, et al.
Publicado: (2021)

First-Line Chemo-Immunotherapy for Extensive-Stage Small-Cell Lung Cancer: A United States-Based Cost-Effectiveness Analysis
por: Liu, Qiao, et al.
Publicado: (2021)

Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis
por: Sathiyapalan, Arani, et al.
Publicado: (2022)

Real-World Efficacy and Safety of Thoracic Radiotherapy after First-Line Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer
por: Xie, Zhaoliang, et al.
Publicado: (2023)

Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China
por: Xiang, Guiyuan, et al.
Publicado: (2023)

Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US
por: Wang, Yingcheng, et al.
Publicado: (2021)

Prolonged Survival in a Patient With Extensive-Stage Small Cell Lung Cancer in Spite of Discontinued Immunotherapy With Atezolizumab
por: Konishi, Kazuhisa, et al.
Publicado: (2023)

Extensive necrosis of visceral melanoma metastases after immunotherapy
por: Stoeter, David, et al.
Publicado: (2008)

Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era
por: Li, Huanhuan, et al.
Publicado: (2023)

Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
por: Wang, Bi-Cheng, et al.
Publicado: (2020)

Consolidative Thoracic Radiation Therapy After First-Line Chemotherapy and Immunotherapy in Extensive-Stage Small Cell Lung Cancer: A Multi-Institutional Case Series
por: Diamond, Brett H., et al.
Publicado: (2021)

Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis
por: Zhang, Tianming, et al.
Publicado: (2023)

Research Progress on the Microenvironment and Immunotherapy of Advanced Non-Small Cell Lung Cancer With Liver Metastases
por: Fang, Yujia, et al.
Publicado: (2022)

Corrigendum to “Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”
por: Wang, Bi-Cheng, et al.
Publicado: (2021)

Systemic Chemotherapy for Progression of Brain Metastases in Extensive-Stage Small Cell Lung Cancer
por: Abdel Karim, Nagla, et al.
Publicado: (2015)

Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer
por: Liang, Xueyan, et al.
Publicado: (2023)

First line Immunotherapy for Non-Small Cell Lung Cancer
por: Nasser, Nicola J., et al.
Publicado: (2020)

Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer
por: Zhou, Fei, et al.
Publicado: (2020)

The Role of Immunotherapy in Extensive Stage Small-Cell Lung Cancer: A Review of the Literature
por: Tsiouprou, Ioanna, et al.
Publicado: (2019)

Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer
por: Li, Lingling, et al.
Publicado: (2022)

Immunotherapy for extensive-stage small-cell lung cancer: current landscape and future perspectives
por: Zhang, Shuang, et al.
Publicado: (2023)

Real-World Analysis of Clinical Characteristics and Survival Outcomes in Patients With Extensive-Stage SCLC Treated With First-Line Chemoimmunotherapy
por: Wang, Yang, et al.
Publicado: (2023)

Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review
por: Zhang, Xu, et al.
Publicado: (2022)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer
por: Liu, Qiao, et al.
Publicado: (2021)

First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions
por: Ortega-Franco, A., et al.
Publicado: (2021)

First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
por: Li, Lijuan, et al.
Publicado: (2023)

Cost‐effectiveness of first‐line immunotherapies for advanced non‐small cell lung cancer
por: Yang, Szu‐Chun, et al.
Publicado: (2023)

Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report
por: Chen, Yuanbin, et al.
Publicado: (2022)

Immunotherapy in extensive small cell lung cancer
por: Verma, Vaibhav, et al.
Publicado: (2019)

The role of thoracic consolidative radiotherapy in the setting of immunotherapy in extensive stage small cell lung cancer
por: Verma, Saurav, et al.
Publicado: (2023)

Chemo-immunotherapy as first-line treatment for small-cell lung cancer
por: Farid, Saira, et al.
Publicado: (2020)

Outcome of immune checkpoint inhibitors in patients with extensive-stage small-cell lung cancer and brain metastases
por: Wang, Chunyu, et al.
Publicado: (2023)

Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis
por: Chen, Hao, et al.
Publicado: (2020)

First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis
por: Hotta, Katsuyuki, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA
por: Ionova, Yelena, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6stq0ikb3h0ah84hrt826qrog1